Dermatología Estado actual de terapias CRISPR: nueva esperanza en el armamento dermatológico
Referencias bibliográficas
Devi
V, Harjai K, Chhibber S. CRISPR-Cas systems: role in cellular processes beyond adaptive
immunity. Folia Microbiol. 2022; 67: 837–50.
Huang
J, Zhou Y, Li J, Lu A, Liang C. CRISPR/Cas systems: Delivery and application in
gene therapy. Front Bioeng Biotechnol. 2022; 10: 942325.
Ain
QU, Campos EVR, Huynh A, Witzigmann D, Hedtrich S. Gene Delivery to the Skin –
How Far Have We Come?. Trends Biotechnol. 2021; 39: 474–87.
De Rosa
L, Latella MC, Secone Seconetti A, et al. Toward Combined Cell and Gene Therapy for
Genodermatoses.Cold Spring Harb Perspect Biol. 2020; 12: 035667.
Bhat
P, Garibyan L. The Potential of CRISPR-Guided Therapies in the Dermatology
Clinic. JID Innov.
2022; 2: 100103.
Bonafont J, Mencía Á, García M, Torres R, Rodríguez S,
Carretero M, et al. Clinically
Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA
CRISPR/Cas9-Mediated Gene Editing. Mol Ther. 2019; 27: 986–98.
Wu W,
Lu Z, Li F, Wang W, Qian N, Duan J, et
al. Efficient in vivo gene editing using ribonucleoproteins in skin stem
cells of recessive dystrophic epidermolysis bullosa mouse model. Proc Natl Acad
Sci U S A. 2017; 114: 1660–1665.
Izmiryan
A, Ganier C, Bovolenta M, Schmitt A, Mavilio F, Hovnanian A. Ex Vivo COL7A1
Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and
Homology-Directed Repair. Mol Ther Nucleic Acids. 2018; 12: 554–67.
Tsai YC, Tsai
TF. Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to
Immunopathogenesis to Phenotypes.Int J Mol Sci. 2022; 23: 5518.
Capon F. The Genetic Basis of
Psoriasis.Int J Mol Sci. 2017; 18: 2526.
Mahil
SK, Catapano M, Di Meglio P, Dand N, Ahlfors H, Carr IM, et al. An
analysis of IL-36 signature genes and individuals with IL1RL2 knockout
mutations validates IL-36 as a psoriasis therapeutic target. Sci Transl Med.
2017; 9: 2514.
Al-Shobaili HA,
Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z. Molecular Genetic of Atopic
dermatitis: An Update.Int J Health Sci (Qassim). 2016; 10: 96-120.
Moosbrugger-Martinz
V, Leprince C, Méchin MC, Simon M, Blunder S, Gruber R, et al.
Revisiting the Roles of Filaggrin in Atopic Dermatitis.Int J Mol Sci.
2022; 23: 5318.
Kezic
S, O’Regan GM, Lutter R, Jakasa I, Koster ES, Saunders S, et al. Filaggrin loss-of-function mutations are associated with
enhanced expression of IL-1 cytokines in the stratum corneum of patients with
atopic dermatitis and in a murine model of filaggrin deficiency. J Allergy Clin Immunol. 2012; 129: 1031-1039.
Primiano
MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, et al. Efficacy and Pharmacology of the NLRP3 Inflammasome
Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary
Inflammation. J Immunol. 2016; 197: 2421–2433.
Wan T, Pan Q,
Ping Y. Microneedle-assisted genome editing: A transdermal strategy of
targetingNLRP3by CRISPR-Cas9 for synergistic therapy of
inflammatory skin disorders.Sci Adv. 2021; 7: 2888.
Lam KN, Spanogiannopoulos P, Soto-Perez P, Alexander
M, Nalley MJ, Bisanz JE, et al.Phage-delivered CRISPR-Cas9 for strain-specific depletion
and genomic deletions in the gut microbiome. Cell Rep. 2021; 37: 109930.
Selle K,
Fletcher JR, Tuson H, Schmitt DS, McMillan L, Vridhambal GS, et al.In
VivoTargeting of Clostridioides difficile Using Phage-Delivered
CRISPR-Cas3 Antimicrobials.mBio. 2020; 11: 00019-20.
Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal Drug Delivery:
Innovative Pharmaceutical Developments Based on Disruption of the Barrier
Properties of the stratum corneum.Pharmaceutics. 2015; 7: 438-470.
NOTA:Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.
Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO, caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit
